What is the appropriate workup for a newly diagnosed urothelial carcinoma?

Workup for Newly Diagnosed Urothelial Carcinoma

For newly diagnosed urothelial carcinoma, perform CT urography (CTU) with corticomedullary phase for comprehensive staging, chest CT for pulmonary evaluation, urethrocystoscopy with voided urine cytology, and diagnostic ureterorenoscopy (URS) with biopsy when imaging and cytology are insufficient for risk stratification. 1, 2

Essential Imaging Studies

CT Urography (CTU) - The Gold Standard

CTU is the single most important imaging modality for diagnosis and staging of urothelial carcinoma. 1 The evidence is compelling:

• Diagnostic accuracy: CTU demonstrates 96% sensitivity (95% CI: 88-100%) and 99% specificity (95% CI: 98-100%) for identifying urothelial carcinoma 1
• Overall accuracy: 91% diagnostic accuracy for detecting urothelial carcinomas 1
• Must include corticomedullary phase for optimal evaluation 3

CTU serves multiple critical functions:

• Local and distant staging
• Detection of synchronous tumors (25-30% of upper tract cases are multifocal) 1
• Evaluation of lymph node involvement
• Assessment of local invasion into renal parenchyma and periureteric tissue

Important caveat: CTU may miss very small or flat lesions that require direct visualization 1. CT cannot detect microscopic tumor metastases in normal-sized lymph nodes 1.

Chest CT

All patients require pulmonary evaluation with chest CT, particularly those with high-risk features. 1, 2 CT chest with IV contrast is preferred over non-contrast for evaluating metastatic disease and lymphadenopathy 1.

Optional Advanced Imaging

• 18F-FDG PET/CT may be used to rule out metastases in high-risk disease 2
• Bone scan is NOT routinely recommended; reserve for patients with bone pain or elevated alkaline phosphatase 1

Endoscopic Evaluation

Urethrocystoscopy

Perform urethrocystoscopy to rule out bladder tumor in all cases. 2 This is essential because:

• Synchronous bladder involvement is common
• Helps determine if disease is isolated to upper tract or involves bladder

Diagnostic Ureterorenoscopy (URS)

Use diagnostic URS when imaging and voided cytology are insufficient for diagnosis and/or risk stratification. 2 This is a strong recommendation from the 2025 EAU guidelines.

During URS, obtain:

• Direct visualization of suspicious lesions
• Focal (barbotage) cytology - more accurate than voided cytology (76% sensitivity vs 63%) 4
• Tissue biopsy using appropriate technique:
  • "Form tackle" basket biopsy for papillary lesions
  • Cold-cup biopsy for flat or sessile lesions 5

Critical limitation: Endoscopic biopsy grade matches final pathology in only 46% of cases, with 44% being upgraded and 10% downgraded 2. This underscores why imaging findings must be integrated into risk assessment.

Cytology

Voided Urine Cytology

Perform voided urinary cytology in any case with suspicion of upper tract tumor. 2

Performance characteristics:

• Sensitivity: 63%
• Specificity: 67% 4

Clinical decision algorithm:

• Normal CT + Normal voided cytology = 100% negative predictive value (no UTUC found) 4
• Abnormal CT + Abnormal voided cytology = 83% had confirmed UTUC 4

Selective (Barbotage) Cytology

During URS, selective cytology improves diagnostic accuracy (76% sensitivity, 73% specificity) 4, though one study suggests it may not significantly contribute beyond other diagnostic modalities 4.

Molecular Testing

Test for FGFR2/3 alterations at initial diagnosis in the metastatic setting. 2 This is a strong recommendation from the 2025 EAU guidelines. Preferably test tissue from an invasive part of the tumor or metastatic site.

Risk Stratification Factors to Document

The workup must establish these critical prognostic factors:

Tumor Grade

• Most important surrogate marker for pathological stage 2
• High-grade tumors strongly correlate with muscle-invasive disease (≥pT2)
• Use both WHO classification systems (1973/1999 and 2004/2016) 3

Tumor Stage

• Primary prognostic factor 2
• 5-year cancer-specific survival: 86% (non-muscle-invasive), 70% (muscle-invasive organ-confined), 44% (locally advanced) 2

CT Findings Predicting High-Risk Disease

• Local invasion on CT (peripelvic fat invasion, non-organ-confined tumor)
• Hydroureteronephrosis
• Tumor size
• Multifocality 2

Histological Subtypes

Document presence of aggressive variants:

• Squamous differentiation
• Sarcomatoid features
• Micropapillary variant All are associated with locally advanced disease and worse outcomes 2

Common Pitfalls to Avoid

1. Do not rely on CT alone for T staging: CT cannot reliably differentiate Ta, T1, and T2 tumors 2
2. Do not skip chest imaging: Even if abdominopelvic imaging appears localized, pulmonary metastases must be excluded 1, 2
3. Do not accept biopsy grade as definitive: 44% of cases are upgraded at final pathology 2
4. Do not order routine bone scans: Only indicated for symptomatic patients 1
5. Do not use standard CT abdomen/pelvis: CTU protocol with urographic phases is essential 1

Alternative Imaging When CT Contraindicated

Perform MRI with urography (MRU) if CT is contraindicated. 2 MRI offers:

• No radiation exposure
• No contrast agents required (can use diffusion-weighted imaging)
• Useful for predicting T stage and tumor grade 6
• Lower spatial resolution than CTU 6